INVO Fertility, Inc (NASDAQ:IVF) Sees Large Growth in Short Interest

INVO Fertility, Inc (NASDAQ:IVF) was the target of a significant increase in short interest in the month of June. As of June 30th, there was short interest totaling 760,242 shares, an increase of 461.7% from the June 15th total of 135,347 shares. Based on an average daily volume of 12,658,939 shares, the days-to-cover ratio is presently 0.1 days. Approximately 42.8% of the shares of the stock are short sold.

INVO Fertility Price Performance

Shares of NASDAQ IVF traded down $0.03 during midday trading on Friday, hitting $1.13. The stock had a trading volume of 106,024 shares, compared to its average volume of 6,563,751. The company has a quick ratio of 0.87, a current ratio of 0.90 and a debt-to-equity ratio of 0.05. The stock has a 50 day simple moving average of $1.58 and a 200-day simple moving average of $3.33. The company has a market capitalization of $2.02 million, a PE ratio of -0.00 and a beta of 2.28. INVO Fertility has a 1 year low of $1.13 and a 1 year high of $169.60.

INVO Fertility (NASDAQ:IVF) last issued its quarterly earnings results on Monday, June 22nd. The company reported ($3.38) EPS for the quarter. INVO Fertility had a negative return on equity of 420.62% and a negative net margin of 183.75%.The firm had revenue of $2.02 million for the quarter.

Institutional Investors Weigh In On INVO Fertility

A hedge fund recently bought a new stake in INVO Fertility stock. Citadel Advisors LLC bought a new stake in INVO Fertility, Inc (NASDAQ:IVF) in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 66,849 shares of the company’s stock, valued at approximately $51,000. Citadel Advisors LLC owned about 1.19% of INVO Fertility as of its most recent SEC filing. 12.02% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, Weiss Ratings raised shares of INVO Fertility from a “sell (e)” rating to a “sell (e+)” rating in a research note on Wednesday, May 6th. One investment analyst has rated the stock with a Strong Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $20.00.

INVO Fertility Company Profile

INVO Fertility (NASDAQ:IVF) is a medical technology company focused on advancing assisted reproductive treatments through innovative in-vivo incubation solutions. The company develops and commercializes devices designed to facilitate fertilization and early embryo development inside a patient’s body, offering an alternative to conventional laboratory-based in vitro fertilization (IVF) techniques.

The company’s flagship product, the INVOcell device, is a single-use, intravaginal incubator that holds a controlled microenvironment for egg and sperm co-incubation.